July 2026 in Oncology: A Look Back at FDA Approvals and Decisions
The July 2026 oncology roundup spotlights rapid cancer drug approvals, new dosing options, a melanoma virus therapy vote, and key rejections shaping treatment trends.
July 2026 brought a dense run of FDA activity across breast, lung, bladder, and blood cancers, along with a pancreatic cancer application that moved through review in a matter of weeks. Four new approvals landed in the space of 2 weeks in the middle of the month, a formulation switch gave patients with multiple myeloma a needle-and-syringe alternative to infusion chairs, and a liver cancer combination hit a regulatory wall for the third time. Meanwhile, an oncolytic virus therapy for melanoma that has already collected 2 rejections heads into an advisory committee meeting this week, setting up one of the more closely watched decisions of the summer. Here is a roundup of the most notable FDA oncology news from July 2026.